Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages

PLoS Medicine

Volumn 7, Issue 4, 2010, Pages

  Gillen, Sonja ^a   Schuster, Tibor ^b   Büschenfelde, Christian Meyer Zum ^a   Friess, Helmut ^a   Kleeff, Jörg ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; META ANALYSIS; MONOTHERAPY; NEUTROPENIA; PANCREAS CANCER; PANCREAS RESECTION; PREOPERATIVE CARE; RADIATION RESPONSE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADJUVANT THERAPY; METHODOLOGY; PANCREAS TUMOR;

ANTINEOPLASTIC AGENTS; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PREOPERATIVE CARE; TREATMENT OUTCOME;

EID: 77951709577     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000267     Document Type: Review

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C (2008) Metaanalysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8: 82.
3. Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, et al. (2008) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 99: 6-13.
4. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, et al. (2007) National failure to operate on early stage pancreatic cancer. Ann Surg 246: 173-180.
5. Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, et al. (2007) Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 14: 118-127.
6. Kleeff J, Friess H, Buchler MW (2007) Neoadjuvant therapy for pancreatic cancer. Br J Surg 94: 261-262.
7. Adler G, Seufferlein T, Bischoff SC, Brambs HJ, Feuerbach S, et al. (2007) [S3-Guidelines "Exocrine pancreatic cancer" 2007]. Z Gastroenterol 45: 487-523.
8. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, et al. (2007) Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 5: 998-1033.
9. Siriwardana HP, Siriwardena AK (2006) Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 93: 662-673.
10. Kleeff J, Reiser C, Hinz U, Bachmann J, Debus J, et al. (2007) Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 245: 566-572.
11. Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, et al. (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15: 1651-1660.
12. Gaedcke J, Gunawan B, Grade M, Szoke R, Liersch T, et al. (2009) The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg.
13. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, et al. (2006) Redefining the R1 resection in pancreatic cancer. Br J Surg 93: 1232-1237.
14. Michalski CW, Kleeff J, Wente MN, Diener MK, Buchler MW, et al. (2007) Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 94: 265-273.
15. Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, et al. (2005) Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 92: 1372-1381.
16. Wolff RA, Varadhachary GR, Evans DB (2008) Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol 15: 2773-2786.
17. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A: 698-703.
18. GITSG (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59: 2006-2010.
19. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, et al. (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230: 776-782; discussion 782-774.
20. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200-1210.
21. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curativeintent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277.
22. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, et al. (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95: 1685-1695.
23. Van Laethem JL, Mornex F, Azria D, van Tienhoven G, Mauer M, et al. (2009) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: updated results of a randomized EORTC/FFCD/GERCOR phase II study (40013-22012/9203). J Clin Oncol 27: 4527.
24. Pilepich MV, Miller HH (1980) Preoperative irradiation in carcinoma of the pancreas. Cancer 46: 1945-1949.
25. Whittington R, Solin L, Mohiuddin M, Cantor RI, Rosato FE, et al. (1984) Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer 54: 1991-1998.
26. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, et al. (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354: 1896-1900.
27. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097. doi:10.1371/journal.pmed.1000097.
28. Tempero M, Alasadi R, Arnoletti JP, Behrman S, Ben-Josef E, et al. (2009) National Comprehensive Cancer Network: Practice guidelines in oncology- v.1.2008: Pancreatic adenocarcinoma. Available at www.nccn.org.
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
30. Freeman MF, Tukey JW (1950) Transformation related to the angular and the square root. Ann Math Statist 21: 607-611.
31. Miller JJ (1978) The inverse of the Freeman-Tukey double arcsine transformation. Am Stat 32: 138.
32. Rouder JN, Speckman PL (2004) An evaluation of the Vincentizing method of forming group-level response time distributions. Psychon Bull Rev 11: 419-427.
33. Thompson SG (1993) Controversies in meta-analysis: the case of the trials of serum cholesterol reduction. Stat Methods Med Res 2: 173-192.
34. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, et al. (2008) Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299: 1019-1026.
35. Schafer M, Mullhaupt B, Clavien PA (2002) Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg 236: 137-148.
36. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, et al. (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346: 1128-1137.
37. Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H, et al. (2003) Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg 138: 1310-1314; discussion 1315.
38. Brunner TB, Grabenbauer GG, Meyer T, Golcher H, Sauer R, et al. (2007) Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer 7: 41.
39. Warshaw AL, Gu ZY, Wittenberg J, Waltman AC (1990) Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 125: 230-233.
40. Neoptolemos J, Buchler M, Stocken DD, Ghaneh P, Smith D, et al. (2009) ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 27: 4505.
41. Hartwig W, Hackert T, Hinz U, Hassenpflug M, Strobel O, et al. (2009) Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg 250: 81-87.
42. Cancer-Research-UK (2009) CancerStats key facts on pancreatic (pancreas) cancer. Available at info.cancerresearchuk.org.
43. Tsai JY, Iannitti DA, Safran H (2003) Combined modality therapy for pancreatic cancer. Semin Oncol 30: 71-79.
44. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, et al. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516.